BKS Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

BKS Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-650	Closed	-$262K	–	222
2018 Q3	$262K	Hold	650	–	–	0.1%	176
2018 Q2	$224K	Sell	650 -100	-13%	-$31.3K	0.08%	200
2018 Q1	$258K	Hold	750	–	–	0.09%	173
2017 Q4	$282K	Hold	750	–	–	0.1%	164
2017 Q3	$335K	Hold	750	–	–	0.13%	143
2017 Q2	$368K	Hold	750	–	–	0.15%	138
2017 Q1	$291K	Hold	750	–	–	0.13%	148
2016 Q4	$275K	Sell	750 -200	-21%	-$76.1K	0.13%	143
2016 Q3	$382K	Sell	950 -1,000	-51%	-$401K	0.18%	112
2016 Q2	$681K	Buy	1,950 +1,000	+105%	+$385K	0.35%	76
2016 Q1	$342K	Buy	+950	New	+$391K	0.18%	113

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BKS Advisors's REGN Position: Q4 2018 in Review

BKS Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 650 shares — an estimated $262K sold.

BKS Advisors first reported a position in REGN in Q1 2016 and held it in 11 quarters. The position peaked at $681K in Q2 2016. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

BKS Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
BKS Advisors sold 650 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $262K.
BKS Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 11 quarters.
BKS Advisors's Regeneron Pharmaceuticals position peaked at $681K in Q2 2016.
670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on BKS Advisors's 13F filing for Q4 2018, filed 30 Jan 2019.